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In this article, we review current evidence linking immune dysfunction in schizophrenia and 
related psychotic disorders focusing particularly on circulating cytokines, oxidative stress and 
cellular markers of inflammation in various stages on illness from drug naïve first episode 
psychosis to chronic schizophrenia. Acute psychotic episode is associated with low-grade 
systemic inflammation in some patients, as reflected by increased concentrations of cytokines 
and other inflammatory markers in peripheral blood. Evidence from general population-based 
longitudinal cohort studies reporting an association between elevated inflammatory markers 
in childhood/adolescence and risk of schizophrenia and related psychosis subsequently in 
adulthood suggest that inflammation could be a causal risk factor for psychosis rather than 
simply be a consequence of illness. Mendelian randomization studies also suggest that 
associations between IL-6, CRP and schizophrenia are likely to be causal. In addition, we 
discuss evidence for disruptions in oxidative stress markers and CSF cytokine levels in 
schizophrenia, and potential reasons for reported trans-diagnostic associations for 
inflammatory cytokines including role of early-life adversity/maltreatment. We argue that 
low-grade inflammation is a clinically useful feature, because it is associated with poor 
response to antipsychotic medication in first episode psychosis. We discuss clinical 
implications for immunological understanding of schizophrenia including scope for clinical 
trials of anti-inflammatory agents, notable gaps in current knowledge, and offer suggestions 






Introduction   
Schizophrenia can be understood as a neurodevelopmental disorder [1, 2], with onset usually 
in early adulthood [3]. Biological research into the pathogenesis of schizophrenia has focused 
on brain structure, function and neurotransmitter abnormalities [4] and genetic risk [5]. 
However, there is also an accepted environmental impact, with a gene and environmental 
(GxE) combined effect related to increased risk, precipitation of illness and/or poorer 
outcomes. Notable environmental factors include childhood trauma, social and economic 
deprivation, minority status and stressful life events [6]. Increasing evidence suggests a role 
for the involvement of immunological processes in mediating the genetic and environmental 
risk for schizophrenia. Indeed, schizophrenia has been associated with an abnormal activation 
of the immune system for many years [7-9]. Previous reviews have summarised evidence 
linking schizophrenia with abnormalities in various components of the immune system; see 
[10, 11], but here, we focus primarily on the evidence on circulating inflammatory cytokines, 
oxidative stress and cellular markers of inflammation. 
 
Cytokines as Key Mediators of Immune Response 
Cytokines are the key signalling molecules that coordinate both innate and adaptive arms of 
the immune system and exert effects in the periphery and the brain. The immune response is 
a highly coordinated process involving an array of cell types that protect the body from harm 
while maintaining tolerance to self-antigens and beneficial organisms. The first arm is our 
“innate” defence mechanisms; older in evolutionary terms and considered to be a first line 
defence. Its cellular components include neutrophils, basophils and eosinophils, monocytes 
and macrophages, dendritic cells and natural killer (NK) cells, which recognise and promote 
defence against pathogens, but lack the sophistication to adapt compared to other more recent 




phase proteins such as C Reactive Protein (CRP), cytokines such as interleukin 6 (IL-6), and 
the compliment cascade, which allow phagocytic cells to clear pathogens (see below).   
 
The second arm of our immune system is the “adaptive” system, which acts on re-exposure to 
a known pathogen. The prime cellular components of the adaptive system include T and B 
lymphocytes. Antibodies produced by B lymphocytes comprise main humoral part of 
adaptive immunity. There is considerable “cross-talk” between the two major arms of the 
immune system. T cells comprise key components of the T Helper 1 (Th1) system and the T 
Helper 2 system (Th2). The Th1 system is polarised towards the production of pro 
inflammatory (activating) cytokines such as interleukin 2 (IL-2), interferon-γ (INF-γ), and 
tumour necrosis factor (TNFα). The Th2 system promotes the generation and maintenance of 
antibody-mediated immune responses as well as production of anti-inflammatory cytokines 
such as interleukin- 4 (IL-4), interleukin-10 (IL-10) and interleukin-13 (IL-13). However, 
cytokines often have pleotropic effect, as for example, IL-6 has both pro and anti-
inflammatory properties. More recently, a key role for the Th17 system has been discovered, 
in regulation of immune response, so this system is important for pathogenesis of a number of 
immune-related disorders [13]. It is now understood that both innate and adaptive systems are 
able to form and retain memory, which influences immune response on re-exposure to a 
stimulus. 
 
Changes in cytokines and their receptor levels have been reported in the blood and 
cerebrospinal fluid (CSF) of patients with schizophrenia [14] – see below. Previously, the 
brain was thought to be protected from peripheral inflammatory responses due to the blood-
brain barrier (BBB). However, it is now clear that cytokines and other circulating 




immune-to-brain communication pathways include direct entry through leaky 
circumventricular areas in the BBB, the lymphatic system, infiltration of immune cells to 
brain, and retrograde axonal transport of immune signal via cranial nerves, for example, the 
Vagus nerve; for a review see [11]. Peripheral or systemic inflammation is therefore relevant 
for neuropsychiatric disorders such as schizophrenia.  
 
Evidence for Cytokine Alteration in Different Stages of Schizophrenia 
Here, we review the evidence for aberrant cytokines in peripheral blood and in CSF in 
patients with schizophrenia and related psychotic disorders. We also discuss evidence from 
epidemiological prospective cohort studies linking elevated inflammatory marker levels in 
childhood/adolescence with risk of psychosis subsequently in adulthood. There is notable 
heterogeneity in existing studies of inflammatory cytokines in schizophrenia as, for example, 
studies have used patients in different stages of illness. Levels of inflammatory markers could 
be influenced by neuroleptic and other drugs, alcohol and illicit drug use, sex, smoking, body 
mass index (BMI), and co-morbid physical illness [12]. Therefore, we have put particular 
emphasis on stage of illness and effects of potential confounders such as those listed above. 
 
Drug Naïve Psychosis 
Studies of medication naive patients are particularly useful to gain a better understanding of 
inflammatory cytokine alteration in schizophrenia. It is well known that antipsychotic 
medication can influence the immune system. Drzyga and colleagues carried out an in vitro 
study showing that antipsychotic drugs affect immune cell function, which often occurs very 
shortly after initial exposure to drug [15]. However, there are mixed results and differing 
effects, including either stimulatory or inhibitory actions. Relatedly, other in vitro studies 




efficacy of some antipsychotic drugs [16]. For example, aripiprazole suppresses apoptosis of 
rodent oligodendrocytes by IFN-γ-activated microglia, and inhibition of TNF-α secretion 
from IFN-γ-activated microglia [17]. Clozapine, the most effective antipsychotic medication, 
influences the immune system. Its effects on white blood cell (WBC) count is well known. 
The drug may have immediate [18]  and longer term effects on IL-6, CRP [19] and high 
sensitivity CRP (hs-CRP) levels [20] in schizophrenia patients.  
 
In a systematic review and meta-analysis published in 2014, we included 14 studies that 
together assessed levels of 20 different cytokines and cytokine receptors in 570 neuroleptic 
naive patients. The majority of these patients had a diagnosis of schizophrenia or 
schizophreniform disorder (81%). Highly significant effect sizes were seen for IL-1β, IL-6, 
sIL2r and TNFα, suggesting that an increase in these cytokines in first episode psychosis 
(FEP) patients, compared with controls, is unrelated to antipsychotic drugs (Figure 1). These 
cytokines play key roles in orchestrating innate immune response; IL-1β and TNF-α are 
responsible for stimulating IL-6 production, while IL-6 signals hepatocytes to produce acute 
phase proteins such as CRP. Some increase in levels of IL-2, IL-4, and IFN-γ were also seen, 
but differecnes in these cytokine levels were not statistically significant. These cytokines 
were measured in studies with small samples, and in fewer studies altogether leading to low 
statistical power.  
 
More recently, a study by Noto et al reported that comorbid depression might influence 
cytokine levels in FEP patients. While increased levels of IL-6, IL-10 and TNFα were found 
in 55 FEP patients overall, compared with controls, patients with depression showed higher 






In an extensive meta-analysis published in 2011, Miller et al explored cytokine function by 
phase of illness in schizophrenia. Assessing 40 studies, they found IL-1β, IL-6 and TGF-β 
were raised in the acute phase of illness (both in relapse patients and in first episode 
psychosis), and reduced with successful treatment [22]. IL-6 correlated to total level of 
psychopathology in 2 out of 5 studies [22]. TNF-α and IL-6 levels were analysed in most 
studies (97 and 156 total studies respectively). It was proposed that these cytokines could be 
state dependant markers of inflammation, resolving with symptom reduction. However, 
elevated levels of IL-6 in childhood measured years before onset of psychosis is associated 
with psychotic symptoms in early-adulthood [23] (see below). Levels of IL-6 and TNF-α are 
also associated with childhood maltreatment  [24], so these cytokines could also be trait 
markers for psychosis. 
 
In first episode psychosis, Mondelli et al measured BDNF, IL-6 and TNF-α in 46 patients. 
Compared to healthy controls, patients had reduced BDNF gene expression, and increased 
IL-6 and TNF-α. History of childhood trauma was associated with lower BDNF mediated 
through IL-6 [25]. In a more recent review, Goldsmith et al investigated acute and chronic 
cytokine changes in schizophrenia, bipolar disorder and depression, which included 40 
studies on acute schizophrenia [26]. In meta-analysis, IL-6, sIL2r, IL-1RA and TNF were 
all significantly raised in acute schizophrenia, bipolar disorder and depression. There was 
more heterogeneity in FEP samples than acute relapse of established schizophrenia. No 
publication bias was reported for IL-6 [27]. These findings suggest that the association of 
increased inflammatory cytokines transcend traditional diagnostic boundaries; for a 





Another meta-analysis reported elevated serum levels of CRP in FEP and chronic 
schizophrenia irrespective of medication status [28]. With regards to association with specific 
symptoms, an association between CRP levels and positive symptoms, but not negative 
symptoms of psychosis was found. However,  Johnsen et al investigated CRP in acute 
psychosis, reporting a particular association with cognitive dysfunctions rather than positive 
symptoms [29]. Studies in healthy volunteers and non-human primates have reported 
association of inflammatory markers with anhedonia-like behaviour and reward alterations 
[30, 31]. So overall, patient and animal studies indicate an association of inflammatory 
markers with positive, negative and cognitive symptoms. 
 
Chronic Schizophrenia 
TNF-α, IL-12, INF-γ and sIL2r have been reported to be elevated in both acute illness and 
stable ‘outpatients’ with chronic schizophrenia. Goldsmith et al found that, compared with 
controls, the levels of IL-6 were significantly increased in chronic schizophrenia, euthymic 
(but not depressed) bipolar disorder and major depressive disorder [26]. IL-1β and sIL2R 
were significantly increased in chronic schizophrenia and euthymic bipolar disorder. TNF-α 
has been suggested as a trait marker of neuroinflammation [27]. Goldsmith et al review 
confirmed that TNF-α was raised in acute schizophrenia compared to controls and remained 
so after treatment. 
 
In meta-analysis of 5 studies, Miller and Culpeper found that 28% of patients with chronic 
schizophrenia have an elevated CRP [32]. In a recent study of 295 patients with 
schizophrenia and 192 with bipolar disorder, CRP was elevated in the schizophrenia even 
after adjusting for age, gender, race, maternal education, smoking status, and BMI but this 




functioning in patients with predominantly chronic schizophrenia has been reported in one 
cross-sectional study [34]. Together these studies suggest poorer cognitive function may be 
associated with enduring neuroinflammation. 
 
Population-based Longitudinal and Mendelian Randomization Studies Examining 
Causality 
Psychological stress can active innate immune response [35], so cytokine elevation during 
acute psychosis could be a consequence of illness rather than be its cause (i.e., reverse 
causality). Therefore, longitudinal studies are need to establish, or refute, a potentially causal 
role of inflammation in the pathogenesis of psychosis. Evidence from population-based 
longitudinal cohort studies from the UK, Finland and Sweden has linked higher levels of IL-
6, CRP and Erythrocyte Sedimentation Rate (ESR) in childhood/adolescence with risk of 
psychotic symptoms or diagnosis of schizophrenia subsequently in adulthood [23, 36, 37]. 
Using data from the Avon Longitudinal Study of Parents and Children (ALSPAC), a general 
population-representative birth cohort, Khandaker et al have reported that higher levels of IL-
6 in childhood at age 9 years is associated with increased risk of psychotic symptoms at early 
adulthood at age 18 years in a linear dose-response fashion [23] (Figure 2). Evidence for this 
association remained after controlling for sex, BMI, social class, ethnicity and childhood 
psychological and behavioural problems preceding the measurement of IL-6. Although in 
ALSPAC, CRP was not associated with psychosis risk, Khandaker and colleagues found that 
in the Northern Finland Birth Cohort (NFBC) 1986 higher levels of CRP in adolescence was 
associated with increased risk of hospitalisation with a diagnosis of schizophrenia 
subsequently in adulthood. Furthermore, there was evidence that higher CRP levels in 
adolescence was associated with earlier age at illness onset [37]. These findings are 




increased risk of late- and very-late-onset schizophrenia subsequently at follow-up [38]. More 
recently, we have conducted a longitudinal study based on Swedish male conscripts which 
found that higher ESR, a marker of systemic inflammation, in early-adulthood is associated 
with increased risk of schizophrenia subsequently in adulthood [36].  
 
Although previous longitudinal studies have controlled for key confounders such as sex, 
BMI, social class, residual confounding still might explain the association between 
inflammatory markers and psychosis. Recently, Khandaker and colleagues have used genetic 
association analysis informed by Mendelian randomization (MR) which indicates that 
residual confounding is unlikely to explain the association between IL-6 and psychosis fully. 
MR is based on the idea that if a biomarker is causally related to an illness, genetic variant(s) 
regulating levels/activity of that biomarker should also be associated with the illness [39]. 
Using data from the ALSPAC birth cohort, we have shown that a genetic variant in the IL-6 
receptor gene (IL6R Asp358Ala; rs2228145) that is known to dampen down inflammation by 
impairing the activity of IL-6 is protective for severe depression and/or psychosis [40]. The 
genetic variant is strongly associated with serum IL-6 and CRP levels, but not with any 
common confounders of the inflammation-psychosis relationship such as sex, social class, 
ethnicity, and BMI. Genetic variants segregate at random during meiosis and are unrelated to 
sociodemographic and other confounders. Therefore, an association between psychosis and a 
genetic variant that regulates IL-6 activity strongly indicates that the IL-6/IL-6R pathways are 
causally linked to psychosis. Similarly, using MR analysis of psychiatric genomic consortium 






Together these studies suggest that reverse causality or residual confounding are unlikely 
explanations for previously observed association between inflammatory markers, particularly 
IL-6, CRP, and psychosis. These associations are likely to be causal, so these biomarkers 
could be novel targets for intervention and prevention of psychotic disorders.   
 
CSF Cytokine Alteration in Schizophrenia 
Meta-analysis of studies of CSF from patients with schizophrenia suggests that levels of 
inflammatory cytokines are increased in patients with psychosis. A meta-analysis of 16 
studies published in 2018 by Wang et al reported that CSF levels of IL-1β, IL-6 and IL-8 
were significantly elevated in schizophrenia patients compared with controls [42]. Similar 
findings were also observed for depression. Whether levels of inflammatory markers in 
peripheral blood corresponds with neuroinflammaton is an important question. This meta-
analysis also reported that many CSF alterations are also concordant with those in the 
peripheral blood, particularly for schizophrenia [42]. This provides some validity to the use 
of peripheral markers of inflammation in schizophrenia research. This finding is consistent 
with a study by Coughlin et al that measured IL-6 in the CSF of patients with recent onset 
schizophrenia also undergoing a positron emission tomography (PET) study of translocator 
protein 18k Da (TSPO), a marker of microglial activation using [11C] DPA-713[43]. Whilst 
non-significant results were seen in the TSPO analysis, IL-6 levels was significantly raised 
in patients compared to controls. Furthermore, the study found IL-6 levels in the CSF 








Oxidative Stress Markers in Acute and Chronic Schizophrenia 
First Episode Psychosis 
Decreased levels of the anti-oxidant, glutathione (GSH), have been reported in patients with 
acute psychosis compared with controls [44, 45]. GSH is an antioxidant which provides 
within cell protection, and when depleted contributes to oxidative stress. Flatlow, Buckly and 
Miller reported a decrease in GSH in acutely relapsed patients with schizophrenia together 
with other anti-oxidants such as superoxide dismutase (SOD) and catalase (CAT), however 
there was significant heterogeneity in reported studies such that SOD and CAT but not GSH 
was reduced in FEP [46]. This may suggest a more persevered oxidative defense earlier in the 
course of illness. 
 
As a substantial minority of patients with FEP do not go on to develop an enduring mental 
illness, and it may be that those with a protective oxidative defense to cellular stress have 
better outcomes [47]. This hypothesis remains to be tested. However Wang et al investigated 
cysteine, a semi-essential amino acid and a precursor of GSH glutathione, as a potential 
indicator of preserved cognitive function in FEP with some positive findings [48]. The 
functional consequences of increased oxidative stress or reduced defence against this 
oxidative stress in the brain are still to be fully understood. Changes in neuronal membrane 
permeability eventually leading to cell death could contribute to grey matter volume (GMV) 
loss seen in schizophrenia [49]. In respect to known neurochemical changes in psychosis, it 
has been proposed that oxidative stress results in over activation of NMDA and altered 
dopamine receptor function.  Whilst schizophrenia is no longer understood within a simplistic 
conclusion of hyperdopaminergia, rather consisting of regionally specific prefrontal 
hypodopaminergia and subcortical hyperdopaminergia, the cumulative effect of overactive or 




receptors are downregulated by oxidation leading to disinhibition of pyramidal cells and 
unregulated glutamatergic excess [51].  
 
Chronic Schizophrenia 
There is substantial evidence of impaired oxidative defense in chronic schizophrenia, as 
reviewed by Flatlow et al in 2013 [46]. Negative symptoms have been associated with low 
levels of GSH, and positive symptoms have been positively correlated with SOD activity. A 
study by Fraguas et al assessed the relationship between GMV and GSH in the brains of 
patients with schizophrenia, with a progressive decline in GMV correlated to declining 
circulating GSH [52]. Thus, the deficit state of some patients with schizophrenia may be 
related to a specific lack of defence against oxidative stress. 
 
There is a great deal of clinical and phenomenological commonality between schizophrenia 
and depression [53]. In schizophrenia, there is substantial glutamate dysfunction including 
clear evidence for Glx abnormality in brain areas such as the posterior medial prefrontal 
cortex (pmPFC). Increased Glx is seen in younger patients or more acute phases of illness, 
whereas reduced Glx has been reported in patients who are older and have residual negative 
symptoms [54]. Just as in schizophrenia, there is substantial evidence for increase in 
peripheral markers of inflammation in MDD. However, co-morbid depression doesn’t solely 
account for increased inflammation in schizophrenia, as evidence for association persists after 
excluding or controlling for depression [55]. Nevertheless, it is possible that the presence of 
both psychosis and depression has a greater impact on immune dysfunction than the sum of 
each individually. Poorer clinical outcomes including increased risk of relapse, low quality of 
life and poor functional outcomes for patients with comorbid depression and schizophrenia 




Early changes in neurochemicals such as Glx may result in more significant impact for those 
individuals with deficient defence against this inflammatory challenge [16]. The effect of 
inflammation includes the generation of reactive oxygen species such as superoxide, 
hydroxyl and peroxyl. The substantial evidence of impaired oxidative defense in early 
psychosis with diminished levels of GSH [44, 45, 57] show that the response of brain 
glutamate to inflammation and associated oxidative stress will also depend on the strength of 
defences against it. Thus, clinically poorer outcomes, such as seen with some subjects with 
depression and schizophrenia, may be related not just to the effect of chronic inflammation 
but also impaired defence against this. 
 
Trans-diagnostic Effect of Inflammation and Potential Role of Early-Life Adversity 
Studies of inflammatory markers in peripheral blood and CSF suggest that inflammation is 
associated with a number of psychiatric disorders including schizophrenia and related 
psychoses [10, 14, 42, 58, 59], depression [60, 61], anxiety [62], post-traumatic stress 
disorder (PTSD) [63], autism [64], Alzheimer’s disease and other dementias [65]. However, 
possible reasons for this apparent trans-diagnostic association of inflammation are unknown. 
We have recently reported that the apparent trans-diagnostic effect may arise from 
association of inflammation with symptoms that are commonly shared between disorders 
[66]. Using a symptom-level data on 10 positive and 10 negative symptoms of psychosis 
assessed in adolescent participants from the from the ALSPAC birth cohort, we have shown 
at the at group level positive and negative symptom dimension scores were associated with 
serum CRP levels in a similar fashion. At individual symptom level, CRP was associated 
with particularly auditory hallucinations and anhedonia. Auditory hallucinations can occur in 
psychosis, depression and anxiety disorders [67]. Anhedonia is both an important negative 




Association between inflammation and anhedonia is supported by experimental studies. In 
non-human primates, chronic, low-dose peripheral interferon administration reduces striatal 
dopamine release in association with anhedonia-like behaviour [68]. In healthy volunteers, 
inflammation induces hedonic alterations (decreased preference for reward and increased 
avoidance of punishment) [30], which resemble anhedonia. Other reasons for this apparent 
trans-diagnostic effect could be shared genes that contributes to inflammation and risk of 
depression and schizophrenia. Genetic overlap between schizophrenia, bipolar disorder and 
depression is well established.  
 
Shared risk factors, particularly early-life adversity, could be another explanation for the 
apparent trans-diagnostic effect of inflammation. Childhood abuse/maltreatment may 
program the immune system leading with increased concentrations inflammatory markers in 
adulthood [24], which in turn, may increase psychiatric risk. In the ALSPAC birth cohort, 
maternal parental depression is associated with higher levels of IL-6 and CRP in childhood 
and with higher risk of depression and psychosis in early-adulthood in offspring [69]. 
Furthermore, childhood IL-6 levels mediate the association between prenatal depression and 
offspring psychosis risk. These findings are consistent with the developmental programming 
hypothesis by David Barker, which posits that exposure to stress during critical period of 
development may program certain physiological system(s) leading to increased risk of 
chronic illnesses of adult life [70]. Early-life adversity is associated with coronary heart 
disease, type-two diabetes, which are common co-morbidities for schizophrenia and 
depression. Young adults with psychotic symptoms display evidence of dysglycaemia, which 
is linked with levels of IL-6 in childhood [71]. Therefore, whether programming of innate 




depression, coronary heart disease and type-two diabetes is an interesting hypothesis that 
needs investigating. 
 
Therapeutic Implications for Low-grade Inflammation in Schizophrenia 
Mondelli et al have reported an association between innate immune activation and poorer 
treatment response in 57 patients with FEP: non-responders (as defined by an absence of 
clinically significant symptom response in keep in with remission criteria at 12 weeks) had a 
significantly higher IL-6 and INF- at baseline. They also reported an aberrant cortisol 
wakening response and suggest this combination of markers may be an early signal of poor 
outcome [72]. Indeed, inflammatory mechanisms, as outlined above, have been cited as one 
of the potential mechanism of effect of Clozapine in treatment resistant schizophrenia.  
 
As well as poor treatment response, makers of inflammation may indicate poorer physical 
health outcomes. Russell et al investigated 53 FEP patients and showed that FEP patients 
with raised CRP were at more risk of developing short-term metabolic abnormalities 
including dyslipidemia, independent of weight-gain [73]. As mentioned earlier, in the 
ALSPAC birth cohort young adults with psychotic symptoms displayed evidence of 
dysglycaemia, which was associated with childhood IL-6 levels [71]. Thus, the potential for 
stratifying treatment approach; early targeting of potential treatment resistance or heightened 
monitoring from adverse effects of antipsychotics shows some promise in a personalized 
approach to FEP and schizophrenia.  
 
Because inflammation is associated with BMI, smoking, alcohol use, physical comorbidity, 
antipsychotic treatment and treatment induced weight gain, further work is needed to 




predicting response to antidepressant/ antipsychotic treatment, and for identifying patients 
who are likely to benefit from immunomodulatory treatments. 
 
Inflammation is unlikely to be relevant for illness pathogenesis in all patients with psychosis. 
For depression, clinical trials indicate that anti-inflammatory drugs may be helpful for 
patients who show evidence of inflammation [74, 75]. Existing RCTs of anti-inflammatory 
drugs for schizophrenia have yielded mixed results [76-78], possibly due to imprecise 
targeting of patients. Patients with psychosis who do show evidence of inflammation may be 
more suitable candidate for RCTs of anti-inflammatory drugs in future. 
 
Conclusions and Future Directions 
For a number of years now there have been considerable efforts to have a better 
understanding of the immunological and inflammatory aspects of schizophrenia, in the hope 
that this might lead to novel approaches to diagnosis and treatment. See text box for key 
clinical findings and questions for future research. Some aspects are becoming clearer. For 
example, accumulating evidence now confirms that inflammation could play a causal role in 
psychosis rather than being an epiphenomenon or result of treatment, other confounders or 
illness itself. An immunological understanding of schizophrenia could be clinically useful. 
Inflammation is associated with poor response to antipsychotics, co-morbid physical illness, 
such as type-two diabetes mellitus [79], and increased all-cause mortality [80]. Therefore, 
measuring inflammation levels (e.g., CRP test) as part of routine clinical assessment of 
psychosis could identify treatable causes of inflammation and potentially guide antipsychotic 
treatment decision. However, the “one size fits all” approach to drug therapy is unlikely to be 





A ley challenge for future is to determine precisely which patients are likely to benefit from 
anti-inflammatory therapies. This would require a consorted approach including immune 
target identification using genomic and other methods, deep immuno-phenotyping of 
psychosis patients to identify cellular source of inflammation, clinical studies to identify 
effect of inflammation on symptom dimensions, followed by experimental medicine and 
animal studies to examine the effects of novel immune-modulating agents on brain and 
behaviour. With regards to certain pathways where there is sufficient evidence for a causal 
association with schizophrenia, e.g., IL-6/IL-6R pathway, the field now needs experimental 
medicine studies based on selected patient groups to test whether targeting these pathways 
with immuno-modulating drugs improve clinical/clinically relevant outcome measures. 
 
Another important avenue for future research would be to understand how inflammation 
influences developmental trajectories of neuropsychiatric symptoms, cognition or functional 
outcome over the life course. Population-based prospective studies and animal experiments 
would be useful for this purpose.  
 
In summary, many of the major advances in our understanding of the links between immune 
system and schizophrenia suggest that immuno-psychiatry is a promising field, which could 
transform our understanding of illness pathogenesis and approaches to treatment and 
prevention for schizophrenia. To be successful, the field requires collaborative working 
among many experts including those from psychiatry, neuroscience, immunology, 








BBB:  Blood–brain barrier 
CRP: C-reactive protein 
TNF-α: Tumour necrosis factor alpha 
IL6: Interleukin-6 
IL-8: Interleukin 8 
CNS: Central nervous system 
MHC: Major histocompatibility complex 
ALSPAC: Avon longitudinal study of parents and children 
CSF: Cerebrospinal fluid 
HPA: Hypothalamic-pituitary-adrenal 
ROS: Reactive Oxygen Series 
Glx: Gutamate/Glutamine ratio 
GSH: Glutathione 










Key Clinical Findings  
• Patients with schizophrenia show evidence of low-grade inflammation detectable in 
in peripheral blood. 
• Inflammation appears to pre-date the onset of illness and be independent of 
medication treatment. 
• Inflammation is associated with poor response to antipsychotic medication. 
Key Clinical Questions 
• What is the relationships between peripheral markers of inflammation and 
structural or functional brain changes? 
• Which patients could benefit from anti-inflammatory therapies? 
• Could measuring inflammation levels in clinical practice help better monitoring of 
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Figure 1: Cytokine Profile in Medication Naive First Episode Psychosis: patients have 
higher IL-1β, TNF-α, IL-6 and sIL-2r levels compared with controls 
Modified from Upthegrove et al. Schizophrenia Research. 2014 May;155(1-3):101-8.  
 
  
STUDY Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper Relativ e Relativ e 
g error Variance limit limit Z-Value p-Value weight weight
IL-1B DiNicola 2012 1.326 0.509 0.259 0.329 2.323 2.608 0.009 6.45
IL-1BSong 2009 1.039 0.175 0.031 0.695 1.383 5.919 0.000 54.13
IL-1 B Theodoropoulou 20011.335 0.206 0.042 0.932 1.739 6.494 0.000 39.42
1.174 0.129 0.017 0.921 1.427 9.095 0.000
-2.00 -1.00 0.00 1.00 2.00






STUDY Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper Relative Relative 
g error Variance limit limit Z-Value p-Value weight weight
TNFa Di Nicola 2012 0.896 0.492 0.242 -0.068 1.861 1.821 0.069 6.54
TNFa Song 2009 0.808 0.171 0.029 0.472 1.144 4.717 0.000 53.98
TNFa Theo 2001 1.137 0.200 0.040 0.744 1.529 5.672 0.000 39.47
0.944 0.126 0.016 0.697 1.190 7.495 0.000
-2.00 -1.00 0.00 1.00 2.00






STUDY Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper Relativ e Relativ e 
g error Variance limit limit Z-Value p-Value weight weight
IL-6 Di Nicola 2012 0.959 0.494 0.244 -0.009 1.928 1.941 0.052 19.51
IL-6 Akliyama 1999 0.923 0.339 0.115 0.259 1.586 2.725 0.006 20.15
IL-6 Borovcain 2012 0.830 0.204 0.041 0.431 1.229 4.079 0.000 20.53
IL-6 Fernandez –Ega 2009 0.524 0.202 0.041 0.129 0.920 2.597 0.009 20.54
IL-6 Ganuili  1989 8.067 0.541 0.293 7.006 9.128 14.903 0.000 19.28
2.206 0.890 0.792 0.462 3.951 2.479 0.013
-4.00 -2.00 0.00 2.00 4.00






STUDY Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper Relativ e Relativ e 
g error Variance limit limit Z-Value p-Value weight weight
sIL2-RRapoport 19941.172 0.414 0.172 0.360 1.984 2.830 0.005 32.74
sIL2-R Akliyama 19991.173 0.348 0.121 0.491 1.855 3.371 0.001 46.39
sIL-2RSirota 2009 1.969 0.519 0.269 0.952 2.986 3.795 0.000 20.87
1.339 0.237 0.056 0.874 1.803 5.649 0.000
-4.00 -2.00 0.00 2.00 4.00









Figure 2: Depression and Psychotic Experiences at Age 18 Years in the Avon 
Longitudinal Study of Parents and Children 
Reproduced with permission from: Khandaker et al. JAMA Psychiatry. 2014;71(10):1121-
1128. 
  
Note: Samples of depression (A) and psychotic experiences (B) were divided by tertiles of 
interleukin 6 (IL-6) in participants at age 9 years. Cutoff values for the top and bottom thirds 
of the distribution of IL-6 values in the total sample (cases and noncases combined) were 
1.08 and 0.57 pg/mL, respectively.  
